About the project
TransBioNet, a new initiative funded by the European Union’s Horizon Europe programme, has been launched to help promising biomedical research across Europe progress towards investment readiness. The nearly €2 million project brings together seven partners from six countries to establish the first pan-European network of knowledge valorisation intermediaries fully dedicated to drug discovery and biomedical innovation.
From biomedical research to investment readiness
In drug discovery, the gap between laboratory discoveries and marketable therapies is particularly difficult to overcome. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), bringing a new medicine to market takes on average more than 10 years, with research and development costs often exceeding €3 billion and success rates as low as just one to two compounds for every 10,000 tested. Amid growing competition, Europe’s share of global commercial drug trials fell by 10 percentage points between 2013 and 2023.
TransBioNet aims to establish the first pan-European network of knowledge valorisation intermediaries fully dedicated to drug discovery and biomedical innovation.
Coordinated by Associação AccelBio in Portugal, the project will address this translation gap through shared assessment tools, training, cross-border collaboration and two Open Calls supporting early-stage drug discovery projects.
How we support innovation
Project assessment
Shared tools to support more standardised evaluations of early-stage drug discovery projects.
Research infrastructure
An atlas mapping research infrastructures and services relevant to biomedical translation across Europe.
Skills and collaboration
Training, peer learning and cross-border secondments to strengthen skills and knowledge exchange among intermediaries.
Open calls
Mentoring and bootcamps for selected projects, with validation funding planned for the highest-ranked.
Have a question about the project?
Write to us about the project, future open calls or opportunities to collaborate.